SoftMedx Healthcare Limited has signed a placing agreement with Advent Securities (Hong Kong) Limited to issue up to 21.42 million new shares at HK$0.280 each, equivalent to 20.00% of the company’s existing share capital and 16.67% of the enlarged share base. All shares will be allotted under the general mandate approved at the 27 May 2026 AGM, so no further shareholder vote is required.
The offer price represents: • a 13.85% discount to the HK$0.325 closing price on 2 November 2026; and • a 19.54% discount to the five-day average closing price of HK$0.348.
If fully placed, the transaction will raise gross proceeds of approximately HK$5.999 million. After deducting the 5% placing commission and related expenses, net proceeds are expected to total about HK$5.67 million, implying a net placing price of roughly HK$0.265 per share. Management plans to deploy the entire net proceeds to support day-to-day operations and bolster the group’s working-capital position.
Upon completion, SoftMedx’s issued share capital will increase from 107.12 million to 128.54 million shares. The new placees—each classified as an independent third party—will collectively hold around 16.67% of the enlarged capital, while other public shareholders will own the remaining 83.33%.
Completion is contingent on Stock Exchange approval for the listing of the new shares and the receipt of all requisite consents. The placing is expected to close within four business days after these conditions are met, though the placing agent retains the right to terminate the deal under specified adverse circumstances.
This fundraising follows two equity issues over the past 12 months: 1.80 billion new shares issued on 11 November 2025 and 16.30 million new shares issued on 10 March 2026.
Comments